France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its ...

The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.

An experimental vaccine for acne could someday transform the way patients with the condition are treated, according to the ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Scientists are testing and working on the world’s first acne vaccine, hoping to offer a long-term alternative to current ...

Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, ...

Sanofi (SNY) stock and Roche (RHHBY) stock trade flat after the duo reaffirmed 2025 forecasts despite strong Q1 results. Read ...

Hello everyone. This is Thomas Kudsk Larsen from the Sanofi IR team. Welcome to the Q1 2025 Conference Call for Investors and Analysts. As usual you can find the slides on sanofi.com. Please turn ...

April 24 (Reuters) - France's Sanofi (SASY.PA), opens new tab reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug ...